Qualigen shares surge 10.62% premarket after shareholder approval confirms Faraday Future's 55% stake and rebrand to AIxCrypto, signaling strategic shift to AI×Web3.

Qualigen Therapeutics surged 10.62% in premarket trading following shareholder approval of a strategic transformation. The company announced it will rebrand as AIxCrypto Holdings, Inc. (NASDAQ: AIXC) on November 20, 2025, after Faraday Future became its majority shareholder with 55% direct equity ownership (63% including affiliates). The rebranding includes governance restructuring, with Faraday Future nominating a majority of board seats, and a shift from biotechnology to a decentralized AI × Web3 technology platform. The news highlights a new three-year roadmap and ecosystem integration plans, positioning AIxCrypto as a gateway to the AI × Web3 era. The approval of share issuances and governance changes, coupled with the anticipated Nasdaq renaming ceremony, signaled a definitive pivot toward high-growth tech sectors, driving investor optimism.